Ciclosporin ophthalmic - Santen SAS

Drug Profile

Ciclosporin ophthalmic - Santen SAS

Alternative Names: Ciclosporin - Santen SAS; Cyclokat; DE 076B; DE 076C; Ikervis; Nova 22007; Vekacia; Verkazia

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novagali Pharma
  • Developer Santen Pharmaceutical; Santen S.A.S.
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Preregistration Allergic conjunctivitis

Most Recent Events

  • 24 Jul 2017 Committee for Medicinal Products for HumanUse (CHMP) recommends approval of ciclosporin for Allergic conjunctivitis (In children, In adolescents) in European Union
  • 23 Jul 2017 Preregistration for Allergic conjunctivitis (In adolescents, In children) in European Union (Ophthalmic) before July 2017
  • 23 Nov 2016 Launched for Dry eyes (In adults) in France (Ophthalmic) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top